381 results on '"Auclin, Edouard"'
Search Results
2. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability
3. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer
4. Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study
5. Real-life implementation and evaluation of the e-referral system SIPILINK
6. TIVAP-related infection due to Gram-negative aerobic bacilli: should TIVAP stay or should it go?
7. Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study
8. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort
9. Biological Rationale for Peripheral Blood Cell–Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer
10. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24)
11. Biomarkers of response to immunotherapy in early stage non-small cell lung cancer
12. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
13. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
14. Validation of a deep learning segmentation algorithm to quantify the skeletal muscle index and sarcopenia in metastatic renal carcinoma
15. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study
16. Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors
17. Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer
18. First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study
19. The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.
20. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort
21. CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17
22. Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression
23. Association between Lung Immune Prognostic Index and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer
24. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer
25. Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade
26. Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
27. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases
28. Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
29. Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients
30. Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study
31. 209 Change of the Neutrophil to Lymphocyte Ratio During Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 Dichloride
32. Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer
33. Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial
34. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study
35. Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma
36. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study
37. Table S3 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
38. Supplementary Methods from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
39. Figure S4 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
40. Tumeurs de Bellini et carcinomes médullaires rénaux à l’ère des nouvelles thérapies
41. Outcomes in elderly patients admitted to the intensive care unit with solid tumors
42. Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma
43. Biomarkers of response to immunotherapy in early stage non-small cell lung cancer
44. Gemcitabine Plus Platinum-Based Chemotherapy in Combination with Bevacizumab for Kidney Metastatic Collecting Duct and Medullary Carcinomas: Results of a Prospective Phase II Trial (BEVABEL- GETUG/AFU24)
45. Clinical Trials, Practice and Design in Gastrointestinal Cancers
46. TIVAP-related infection due to Gram-negative aerobic bacilli: should TIVAP stay or should it go?
47. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score
48. Change of the Neutrophil-to-Lymphocyte Ratio during Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 Dichloride
49. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX ‐bevacizumab failure for COlorectal cancer ( BEFLICO ): An AGEO multicenter study
50. Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.